Some of the names on the move ahead of the open.» Read More
In case you weren't aware, tomorrow is "World Osteoporosis Day" or WOD, for short, as the International Osteoporosis Foundation hilariously refers to it, but biotech Amgen won't be celebrating the occasion.
This Friday the CDC is expected to start giving weekly updates on where and how much H1N1 vaccine has been shipped. I'm curious what the demand will truly turn out to be. Some people are growing concerned about the increasing number of pediatric deaths from H1N1 and may rush to get their kids and themselves vaccinated. Others are afraid of or paranoid about the vaccine.
Vanda Pharmaceuticals may go down in industry history as one of the most remarkable turnaround stories.
Dow component Johnson & Johnson—the first major health care company to report earnings this quarter—posted weaker-than-expected quarterly revenue on Tuesday. Mike Weinstein, managing director and senior medical technology analyst at JPMorgan, offered his analysis of JNJ.
Yesterday and today thousands of kids and healthcare workers around the country started getting AstraZeneca's H1N1 FluMist, the vaccine that's sprayed into the nose. The first shots from Novartis and Sanofi-Aventis may be available later this week. GlaxoSmithKline and Baxter are still waiting for the FDA to approve their vaccines.
The CDC announced today that healthcare workers in Tennessee and Indiana would be amongst the first to get swine flu vaccinations. The outbreak of the H1N1 swine flu virus has sadly killed over 3,900 peope per a report by the World Health Organization (WHO) on September 25th. At the same time the race to battle the pandemic has propped up the shares of biotech companies that promise solutions.
The number-one H1N1 flu concern among U.S. businesses is the availability of a vaccine for employees, according to a new survey by the Business Roundtable.
Major US companies are bracing for a potentially stronger strain of swine flu this year that could threaten the nation's already fragile economic recovery.
The drug biz is abuzz over social media. It's the new frontier. For a lot of PR and corporate communications teams it's all about new media and social media. Some biopharmas, big and small, now have directors of social media. Most are still trying to find their way, but the Food and Drug Administration may soon direct them.
So far, it hasn't been a September to remember on Wall Street. With three days in the books, the month is living up to its historic billing as the worst month of the year for stock investors, though Wednesday's losses were relatively small. Read and listen to what the pros had to say...
Stocks continued to rise on Tuesday after encouraging reports on home prices and consumer confidence. The Treasury auctioned off $42 billion in 2-year notes today, and it was met with mediocre demand. Pres. Obama officially reappointed Ben Bernanke for another term as Fed chairman. Watch and listen to what the pros had to say...
Am I missing something? Or is this not the way to go about advancing your cause?
The London “Daily Mail” has published photos of the flames and aftermath at the Austrian vacation home of Novartis CEO Dr. Daniel Vasella. The arsonists claim to have used nearly 16 gallons of gasoline to ignite the blaze. It was reportedly set at 3:30 in the morning.
On this website for something called "Bite Back" magazine a group identifying itself as MFAH Austria is claiming responsibility for the recent attacks on Swiss drugmaker Novartis and its employees, including CEO Dr. Daniel Vasella.
Stocks ended flat Tuesday as investors took a breather after Monday's blockbuster rally. Bank and airline stocks were bright spots, while investors sold tech, materials and energy. Pending-home sales jumped 3.6 percent in June, beating expectations. It was the fifth straight monthly gain and the longest such streak in six years. Read and listen to what the pros had to say...
Reports surfaced this morning that animal rights activists are suspected of setting fire to and badly damaging the vacation home of Novartis CEO Daniel Vasella in the wee hours of the morning yesterday.
The drug companies help pay my salary. Not directly, of course (although I bet there are conspiracy theorists out there who are probably convinced they do), but they undoubtedly contribute a sizeable amount of advertising dollars to the company I work for.
Investors are placing their bets ahead of a string of pharma earnings due both this week and next. What must you know?
Earnings season should provide a fresh view of the U.S. economy and may shake the stock market out of its summer doldrums.
As the Markey-Waxman bill on carbon emissions cap-and-trade makes it way through the Senate, a new carbon-counting reality may soon be here for American businesses.